OAPN Statin Prescribing Guide
Detailed App Info:
Application Description
This Oxford American Pocket Notes source of information is developed by MedHand Mobile Libraries. Improve your performance with relevant, valid material which is accessed quickly and with minimal effort in the palm of your hand.
The first HMG-CoA reductase inhibitor (statin), lovastatin, has been on the market since 1987. In that time, five more drugs from this class, atorvastatin, pravastatin, fluvastatin, rosuvastatin and simvastatin, have been approved by the FDA. Statins, among the top ten most commonly prescribed drugs in the U.S., are now recommended as first-line treatments by all major regulatory agencies in the U.S. and elsewhere.
As shown in numerous clinical trials, statins are extremely powerful and effective in reducing LDL cholesterol, accompanied by a significant reduction of cardiac events and strokes. As a class, they are well-tolerated by most patients and are easy to administer. However, the withdrawal of cerivastatin (Baycol) from the market in 2001 due to severe myopathy in some patients, has led to increased concern among clinicians with respect to this and other side effects, such as liver and kidney disease. Some studies suggest that this has led to increased reluctance among clinicians to initiate a statin drug regimen or to adjust dosage to increase therapeutic effect. While a small minority of patients do develop serious complications while on statin therapy, current clinical evidence strongly suggests that the benefits of timely statin administration significantly outweigh the risks.
Oxford American Pocket Notes: Statin Prescribing Guide aims to provide clinicians with concise, easily accessible guidance on prescribing statins in various clinical settings. This volume features evidence-based discussion on the indications, pharmacokinetics and safety profiles of the available statins and how these properties translate into selection of the appropriate treatment regimen for the individual patient. Useful tools, such as treatment algorithms, charts, tables and illustrations greatly help enhance the value of this volume as a portable reference tool.
Authors: Ragavendra R Baliga
________________________________________
MedHand Mobile Libraries offers a SUBSCRIPTION FREE application without edition upgrade. MedHand is the exclusive partner of Oxford University Press, publishing the latest editions of their Medical Handbooks in digital format.
MedHand offers user-friendly, quick and intuitive applications for medical books on iPhone, iPod and iPad, supporting you with mobile knowledge at the point of care. Offering the most trusted and well recognized medical guidelines provided by excellent publishers. MedHand delivers what you need, trusted knowledge at the point of care!
The first HMG-CoA reductase inhibitor (statin), lovastatin, has been on the market since 1987. In that time, five more drugs from this class, atorvastatin, pravastatin, fluvastatin, rosuvastatin and simvastatin, have been approved by the FDA. Statins, among the top ten most commonly prescribed drugs in the U.S., are now recommended as first-line treatments by all major regulatory agencies in the U.S. and elsewhere.
As shown in numerous clinical trials, statins are extremely powerful and effective in reducing LDL cholesterol, accompanied by a significant reduction of cardiac events and strokes. As a class, they are well-tolerated by most patients and are easy to administer. However, the withdrawal of cerivastatin (Baycol) from the market in 2001 due to severe myopathy in some patients, has led to increased concern among clinicians with respect to this and other side effects, such as liver and kidney disease. Some studies suggest that this has led to increased reluctance among clinicians to initiate a statin drug regimen or to adjust dosage to increase therapeutic effect. While a small minority of patients do develop serious complications while on statin therapy, current clinical evidence strongly suggests that the benefits of timely statin administration significantly outweigh the risks.
Oxford American Pocket Notes: Statin Prescribing Guide aims to provide clinicians with concise, easily accessible guidance on prescribing statins in various clinical settings. This volume features evidence-based discussion on the indications, pharmacokinetics and safety profiles of the available statins and how these properties translate into selection of the appropriate treatment regimen for the individual patient. Useful tools, such as treatment algorithms, charts, tables and illustrations greatly help enhance the value of this volume as a portable reference tool.
Authors: Ragavendra R Baliga
________________________________________
MedHand Mobile Libraries offers a SUBSCRIPTION FREE application without edition upgrade. MedHand is the exclusive partner of Oxford University Press, publishing the latest editions of their Medical Handbooks in digital format.
MedHand offers user-friendly, quick and intuitive applications for medical books on iPhone, iPod and iPad, supporting you with mobile knowledge at the point of care. Offering the most trusted and well recognized medical guidelines provided by excellent publishers. MedHand delivers what you need, trusted knowledge at the point of care!
Requirements
Your mobile device must have at least 2.13 MB of space to download and install OAPN Statin Prescribing Guide app. OAPN Statin Prescribing Guide was updated to a new version. Purchase this version for $9.99
If you have any problems with installation or in-app purchase, found bugs, questions, comments about this application, you can visit the official website of MedHand – Mobile Libraries MedHand International at http://www.medhand.com.
Copyright © MedHand 2011
